Cargando…

Vulnerability of progeroid smooth muscle cells to biomechanical forces is mediated by MMP13

Hutchinson-Gilford Progeria Syndrome (HGPS) is a premature aging disease in children that leads to early death. Smooth muscle cells (SMCs) are the most affected cells in HGPS individuals, although the reason for such vulnerability remains poorly understood. In this work, we develop a microfluidic ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Pitrez, Patricia R., Estronca, Luís, Monteiro, Luís Miguel, Colell, Guillem, Vazão, Helena, Santinha, Deolinda, Harhouri, Karim, Thornton, Daniel, Navarro, Claire, Egesipe, Anne-Laure, Carvalho, Tânia, Dos Santos, Rodrigo L., Lévy, Nicolas, Smith, James C., de Magalhães, João Pedro, Ori, Alessandro, Bernardo, Andreia, De Sandre-Giovannoli, Annachiara, Nissan, Xavier, Rosell, Anna, Ferreira, Lino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431909/
https://www.ncbi.nlm.nih.gov/pubmed/32807790
http://dx.doi.org/10.1038/s41467-020-17901-2
Descripción
Sumario:Hutchinson-Gilford Progeria Syndrome (HGPS) is a premature aging disease in children that leads to early death. Smooth muscle cells (SMCs) are the most affected cells in HGPS individuals, although the reason for such vulnerability remains poorly understood. In this work, we develop a microfluidic chip formed by HGPS-SMCs generated from induced pluripotent stem cells (iPSCs), to study their vulnerability to flow shear stress. HGPS-iPSC SMCs cultured under arterial flow conditions detach from the chip after a few days of culture; this process is mediated by the upregulation of metalloprotease 13 (MMP13). Importantly, double-mutant Lmna(G609G/G609G)Mmp13(−/−) mice or Lmna(G609G/G609G)Mmp13(+/+) mice treated with a MMP inhibitor show lower SMC loss in the aortic arch than controls. MMP13 upregulation appears to be mediated, at least in part, by the upregulation of glycocalyx. Our HGPS-SMCs chip represents a platform for developing treatments for HGPS individuals that may complement previous pre-clinical and clinical treatments.